Effect of Chronic Valproic Acid Use on Anterior Cerebral Blood Flow of Children with Idiopathic Generalized Epilepsy

Hamit Ozyurek1, Ilkay Bayrak2, Ozlem Yayici Koken3

  • 1the Department of Pediatrics, Pediatric Neurology Division, Ondokuz Mayis University;Pediatric Neurology Unit, Ministry of Health Ankara City Hospital.

Insights

Valproic acid (VPA) treatment for epilepsy in children did not alter cerebral blood flow. However, further research is needed to determine if VPA impacts neurocognition in these patients.

Area of Science:

  • Neurology
  • Pediatrics
  • Medical Imaging

Background:

  • Antiepileptic drugs are associated with neurocognitive deficits.
  • Cerebral blood flow changes are hypothesized to contribute to these deficits.
  • Valproic acid (VPA) is a common antiepileptic drug used for idiopathic generalized epilepsy (IGE).

Purpose of the Study:

  • To investigate the effect of VPA on cerebral blood flow in children with IGE.
  • To determine if VPA treatment alters key hemodynamic parameters in pediatric patients.

Main Methods:

  • Doppler and spectral measurements were performed on 33 children with IGE on VPA and 34 age-matched controls.
  • Measurements included common carotid artery (CCA), internal carotid artery (ICA), external carotid artery (ECA), anterior cerebral artery (ACA), and middle cerebral artery (MCA).
  • Calculated parameters included maximum velocity (VM), end-diastolic velocity (EDV), resistive index (RI), pulsatility index (PI), and flow rate (FR).

Main Results:

  • No statistically significant differences were observed in VM, EDV, RI, PI, or FR between the VPA group and controls.
  • These hemodynamic parameters were measured in the bilateral ICA, ACA, and MCA.
  • The study included children with a mean age of approximately 9.5 years, with a follow-up of over 17 months.

Conclusions:

  • Therapeutic doses of VPA did not demonstrate an effect on anterior cerebral blood flow in children with IGE.
  • Despite no observed changes in cerebral blood flow, it remains challenging to definitively rule out neurocognitive deterioration in patients receiving VPA.
  • Further investigation is warranted to fully understand the relationship between VPA, cerebral blood flow, and neurocognitive outcomes in pediatric epilepsy patients.
Abstract

Related Concept Videos

Antiepileptic Drugs: Modulators of Neurotransmitter Release Mediated by SV2A Protein01:20

Antiepileptic Drugs: Modulators of Neurotransmitter Release Mediated by SV2A Protein

Antiepileptic drugs, such as levetiracetam (Keppra) and brivaracetam (Briviact), have emerged as crucial tools in managing epilepsy. These medications exert their therapeutic effects by targeting the synaptic vesicle protein SV2A, a transmembrane glycoprotein primarily found in the brain.
SV2A is a transmembrane glycoprotein located predominantly in the brain, modulating the release of neurotransmitters for neuronal communication. Both levetiracetam and brivaracetam exhibit a high affinity for...
486
Antiepileptic Drugs: GABAergic Pathway Potentiators01:18

Antiepileptic Drugs: GABAergic Pathway Potentiators

γ-aminobutyric acid or GABA, plays a pivotal role as an inhibitory neurotransmitter in the brain. GABA pathway potentiators, also known as GABAergic drugs, are a class of pharmaceutical agents designed to enhance the functioning of the GABAergic system. These medications primarily treat epilepsy, a neurological disorder characterized by recurrent seizures.
The key GABA pathway potentiators used in epilepsy management are as follows.
Benzodiazepines are a well-known class of drugs used for...
747
Antiepileptic Drugs: Glutamate Antagonists01:14

Antiepileptic Drugs: Glutamate Antagonists

Glutamate is a fundamental neurotransmitter in the central nervous system, playing a vital role in neuronal communication and various cognitive processes. Glutamate stands as the principal excitatory neurotransmitter in the brain. Its presence is crucial for the communication between neurons, underpinning essential processes such as synaptic transmission, neuronal excitability, and plasticity. These functions are vital for higher-order cognitive processes, including learning and memory. The...
549
Antiepileptic Drugs: Potassium Channel Activators01:20

Antiepileptic Drugs: Potassium Channel Activators

Ezocgabine or retigabine, an antiepileptic drug of remarkable efficacy, has revolutionized the management of seizures. It is a potassium channel activator, explicitly targeting the family of Q subtype potassium channels. It enhances the transmembrane potassium currents, regulating neuronal excitability. This action stabilizes the resting membrane potential, a pivotal factor in mitigating the hyperexcitability that characterizes epilepsy.
Ezogabine has gained approval as an adjunctive treatment...
311
Antiepileptic Drugs: Sodium Channel Blockers01:08

Antiepileptic Drugs: Sodium Channel Blockers

Antiepileptic drugs are specialized medications that prevent seizures in individuals diagnosed with epilepsy. These drugs primarily function by blocking the movement of sodium ions through channels in the neuronal membrane, inhibiting the repetitive firing of action potentials often associated with seizures.
Sodium channel blockers modulate ion channels, particularly voltage-gated sodium channels. They block only sodium ion movement.
Among the most commonly prescribed antiepileptic drugs are...
1.0K
Antiepileptic Drugs: Calcium Channel Blockers01:17

Antiepileptic Drugs: Calcium Channel Blockers

Calcium channel blockers, a class of antiepileptic drugs, regulate the flow of calcium ions within neurons.
Calcium channel blockers exert their antiepileptic effects by targeting T-type calcium channels, which are integral to transmitting nerve signals in the central nervous system. These channels allow the passage of calcium ions, which are vital for neuronal communication. By inhibiting T-type calcium channels, calcium channel blockers effectively reduce the release of neurotransmitters and...
704